IFNA1 and neoplasm: In this respect, we previously developed VSV-IFNß as an oncolytic platform [28,29,30], which expresses IFNß [29] to further repress its replication in normal cells [31,32,33], increase the immunogenicity of dying tumor cells and improve its clinical safety and efficacy [29,34,35].